Permanent Discontinuation of Glucocorticoids in Polymyalgia Rheumatica Is Uncommon but May Be Enhanced by Amino Bisphosphonates

Alessandro Giollo, Maurizio Rossini, Francesco Bettili, Francesco Ghellere, Elena Fracassi, Luca Idolazzi, Davide Gatti, and Ombretta Viapiana

ABSTRACT. Objective. The duration of treatment with glucocorticoids (GC) in polymyalgia rheumatica (PMR) is often long-term. Amino bisphosphonates (N-BP) are used in PMR for the prevention of GC-induced osteoporosis, but they could also have immunomodulatory properties. Whether they can be effective as an adjuvant treatment in PMR is unknown. We aimed to establish whether the use of N-BP in our PMR cohort may be associated with GC discontinuation.

Methods. We conducted a retrospective review of all patients diagnosed with PMR recorded in our electronic medical notes. Cox regression analyses were used to examine the association between the use of N-BP and discontinuation of GC.

Results. Data were retrieved for 385 patients (mean age 71 ± 10 yrs, 64% females, mean initial prednisone dose 19 ± 9 mg/day). The median follow-up time was 38 months (range 9–57); more than 60% of patients were exposed to N-BP. GC were discontinued in 47% of patients after a median time of 20 months (range 14–27), but subsequently restarted in 39%. Overall, 276/385 patients (72%) were actively treated at their last available evaluation (mean prednisone dose 4.9 ± 5.5 mg/day), while 123/205 (60%) were still receiving GC after 24 months of followup. The use of N-BP was associated with the discontinuation of GC (adjusted HR 0.66, 95% CI 0.50–0.88), independent of age, initial GC dose, and osteoporosis.

Conclusion. Unlike current guidelines, long-term treatment with GC is often necessary. These preliminary data suggest that N-BP may be involved in the management of PMR. (First Release November 1, 2018; J Rheumatol 2019;46:318–22; doi:10.3899/jrheum.180324)

Key Indexing Terms: POLYMYALGIA RHEUMATICA GLUCOCORTICOIDS BISPHOSPHONATE OSTEOPOROSIS

Polymyalgia rheumatica (PMR) is a chronic inflammatory disease in older adults that causes pain, stiffness, and inflammation of the shoulder and pelvic girdles. It is typically associated with an increase of acute-phase reactants, and up to one-fifth of patients with PMR also have concomitant giant cell arteritis. Glucocorticoids (GC) are still currently the mainstay treatment for PMR, and generally it is proposed that GC would be discontinued about 1 year after the diagnosis. Despite current guidelines, many patients with PMR are unable to stop GC treatment within this time frame. Observational data showed that 40% of patients with PMR would continue GC for longer than 4 years. The median duration of GC therapy had indeed been increasing between 1989 and 2008 within the United Kingdom, reaching 57 weeks in men and 64 weeks in women. In the United States, the median time to permanent discontinuation of GC was almost 6 years between 2000 and 2015.

These data suggest that there is a reluctance to discontinue GC in patients with PMR and our clinical perception agrees with this. PMR is generally considered a benign disease of the elderly; however, GC-related adverse events are a matter of concern. There is an unmet need for identifying the characteristics of those patients with PMR at risk of long-term GC use. GC-related adverse events can occur in up to 85% of treated cases, particularly GC-induced osteoporosis (GIO) and fractures. A retrospective cohort study conducted using primary care records from the UK-based Clinical Practice Research Datalink showed that the risk of...
fracture is increased by 63% in PMR compared with the control population. For the prevention or treatment of GIOP, amino bisphosphonates (N-BP) are recommended as the first-line option for individuals at moderate or high risk of fracture, alongside calcium and vitamin D supplements.

In more recent years, there has been increasing interest in the analgesic, antiinflammatory, and immunomodulatory effects of N-BP. In our study, we aimed to establish the proportion of patients with PMR receiving active treatment with GC in our cohort, and the potential predictors of longterm GC use. In particular, we investigated whether the use of N-BP may be associated with GC discontinuation in PMR.

**MATERIALS AND METHODS**

**Study population and design.** Clinical data were collected retrospectively from electronic medical records (EMR) of our rheumatology unit. Data extraction from more than 10,000 EMR was performed in January 2017, returning 467 records containing the entry “polymyalgia rheumatica.” The local Ethical Committee approved the study (approval number: CE 1876). Written informed consent from patients to publish the material was not requested for this observational study.

**Data collection.** Patients were eligible for inclusion if (1) they had at least 2 distinct assessments recorded in their EMR; (2) they had no previous treatment with GC for PMR; and (3) they fulfilled the 2012 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Polymyalgia Rheumatica. The following exclusion criteria were applied: (1) any history of large-vessel vasculitis; and (2) other diagnosis that could explain the symptoms (e.g., rheumatoid arthritis, connective tissue disease, infection, or cancer). Each EMR was reviewed separately to identify the dosage of GC used (in prednisone equivalent), conventional synthetic disease-modifying antirheumatic drugs (csDMARD), concomitant treatment comorbidities, and inflammatory markers [erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)]. The prescribed GC dosage was tracked from the start of GC until the last available assessment.

**Definitions.** The followup time was defined as the time between the first dose of GC and the last evaluation available in the records. The time to first GC discontinuation was defined as the time between the first dose and the first discontinuation of GC therapy. Peripheral involvement was defined as a synovitis detected by physical examination or imaging. Disease relapse was defined as an increase in GC dosage owing to symptoms attributed to PMR, inflammatory markers, or both; short bursts of GC used for any other inflammatory conditions were not included. Patients treated with N-BP received 1 or more of alendronate, risedronate, ibandronate, or zoledronic acid. When prescribed, N-BP are started routinely per standard practice when the first dose of GC is given. Exposure to N-BP was considered only if the drug was continued for at least 3 months for alendronate, risedronate or ibandronate, or if a patient had at least 1 infusion of zoledronate. Osteoporosis was defined as a T score < 2.5 at spine or hip. Active GC treatment was defined as a patient receiving GC at the last evaluation available in their EMR.

**Statistical analysis.** Data are reported as mean (SD) for continuous variables or percentages for categorical variables. Time intervals are reported as median and interquartile range (IQR). Between-group comparisons of categorical variables were performed by Pearson chi-square test. Univariable and multivariable Cox regression models were used to examine the association between potential predictors and active treatment as the main outcome. Linear relationships between GC dosage and variables of interest were analyzed by Pearson correlation coefficient. Logistic regression was used to identify the characteristics associated with the use of N-BP medications. All statistical analyses were performed using SPSS Version 20 (SPSS Inc.) and statistical significance was identified by 2-tailed p < 0.05.

**RESULTS**

**Baseline characteristics of patients.** The study population consisted of 385 patients (mean age 71 yrs, females 64%). Baseline characteristics are summarized in Table 1. About 30% of patients had some peripheral involvement, mostly olioarticular. Inflammatory markers were increased at baseline with a mean ESR of 49 mm/h and CRP of 33 mg/l. The average dosage of prednisone was 19 mg daily (range 2–50 mg daily), and it was weakly correlated with age (r = 0.117, p = 0.022), hemoglobin (r = −0.134, p = 0.009), CRP (r = 0.153, p = 0.003), and ESR (r = 0.121, p = 0.017). One in every 5 patients was receiving treatment with at least 1 csDMARD during followup, mostly with low-dose weekly methotrexate (MTX; range 7.5–20 mg). More than 60% of patients were treated with N-BP, of whom 26% were diagnosed with osteoporosis at baseline.

**Characteristics of followup.** Data were collected over a median follow period of 37.7 months (IQR 37.9). Among the 385 patients evaluated at baseline, 205 (53%) were followed up to 24 months. Overall, 276 patients (72%) were still receiving active treatment with GC [mean prednisone dose at last visit 4.9 (5.5) mg daily] at their last available evaluation. Disease flares occurred in 307 patients (80%), on average 1 (1) flare per patient. GC were discontinued in 180 patients (47%; mean time to discontinuation 24.0 mos [IQR 20.3]). Nonetheless, GC were restarted in 71/180 patients (39%).

**Factors associated with persistent treatment with GC.** Cox regression analyses were used to establish the factors associated with longterm use of GC, and the results are shown in Table 2. The univariable analysis showed that these factors were associated with persistence in therapy: older age, number of relapses, peripheral involvement, and higher CRP.

**Table 1.** Baseline clinical characteristics and demographics of 385 patients with polymyalgia rheumatica.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, yrs</td>
<td>71 (10)</td>
</tr>
<tr>
<td>Female sex, n (%)</td>
<td>246 (64)</td>
</tr>
<tr>
<td>Peripheral joint involvement, n (%)</td>
<td>113 (29)</td>
</tr>
<tr>
<td>Hemoglobin, g/dl</td>
<td>13 (1)</td>
</tr>
<tr>
<td>ESR, mm/h</td>
<td>49 (25)</td>
</tr>
<tr>
<td>CRP, mg/l</td>
<td>33 (34)</td>
</tr>
<tr>
<td>Initial prednisone dosage, mg daily</td>
<td>19 (9)</td>
</tr>
<tr>
<td>csDMARD at baseline, n (%)</td>
<td>86 (22)</td>
</tr>
<tr>
<td>Methotrexate, n (%)</td>
<td>69 (18)</td>
</tr>
<tr>
<td>Hydroxychloroquine, n (%)</td>
<td>19 (5)</td>
</tr>
<tr>
<td>N-BP, n (%)</td>
<td>240 (62)</td>
</tr>
</tbody>
</table>

Values are mean (SD) unless otherwise specified. CRP: C-reactive protein; csDMARD: conventional synthetic disease-modifying antirheumatic drugs; ESR: erythrocyte sedimentation rate; SD: standard deviation; N-BP: amino bisphosphonates.
These were associated with discontinuation: a higher initial dosage of GC, higher hemoglobin, osteoporosis, and the use of N-BP. Except for osteoporosis, all predictors significantly associated with the outcome at univariable analysis were confirmed in multivariable analysis (Table 2). The use of N-BP had the higher association with the outcome (Figure 1). Moreover, the positive association between N-BP and GC discontinuation retained statistical significance even after the exclusion of patients with peripheral involvement or treatment with MTX (data not shown). A subanalysis only of patients with a followup over 24 months confirmed the significant association between N-BP and treatment duration.

<table>
<thead>
<tr>
<th>Predictor</th>
<th>Univariable HR</th>
<th>Univariable 95% CI</th>
<th>p</th>
<th>Multivariable HR</th>
<th>Multivariable 95% CI</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>1.03</td>
<td>1.02–1.05</td>
<td>&lt; 0.001</td>
<td>1.02</td>
<td>1.01–1.04</td>
<td>0.009</td>
</tr>
<tr>
<td>Female sex</td>
<td>0.86</td>
<td>0.67–1.10</td>
<td>0.220</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initial prednisone dose</td>
<td>0.98</td>
<td>0.97–0.99</td>
<td>0.005</td>
<td>0.96</td>
<td>0.95–0.98</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>No. flares</td>
<td>1.23</td>
<td>1.08–1.40</td>
<td>0.002</td>
<td>0.86</td>
<td>0.73–1.02</td>
<td>0.076</td>
</tr>
<tr>
<td>Peripheral involvement</td>
<td>1.49</td>
<td>1.15–1.93</td>
<td>0.009</td>
<td>1.38</td>
<td>1.05–1.83</td>
<td>0.023</td>
</tr>
<tr>
<td>ESR</td>
<td>1.00</td>
<td>0.99–1.01</td>
<td>0.146</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRP</td>
<td>1.30</td>
<td>1.17–1.43</td>
<td>&lt; 0.001</td>
<td>1.29</td>
<td>1.14–1.45</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>Hemoglobin</td>
<td>0.89</td>
<td>0.81–0.96</td>
<td>0.004</td>
<td>0.86</td>
<td>0.78–0.95</td>
<td>0.004</td>
</tr>
<tr>
<td>N-BP</td>
<td>0.66</td>
<td>0.52–0.85</td>
<td>0.001</td>
<td>0.65</td>
<td>0.49–0.85</td>
<td>0.002</td>
</tr>
<tr>
<td>csDMARD</td>
<td>0.93</td>
<td>0.71–1.23</td>
<td>0.610</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Osteoporosis</td>
<td>0.68</td>
<td>0.52–0.89</td>
<td>0.006</td>
<td>0.75</td>
<td>0.55–1.02</td>
<td>0.066</td>
</tr>
</tbody>
</table>

ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; csDMARD: conventional synthetic disease-modifying antirheumatic drugs; N-BP: amino bisphosphonates.

Table 2. Univariable and multivariable analyses of factors associated with a persistent treatment with glucocorticoids (Cox regression).

*Figure 1. Risk function of longterm glucocorticoid use for the use of amino bisphosphonates (N-BP); adjusted HR 0.65 (95% CI 0.49–0.85), p = 0.002.*
for 1 year, a significant reduction of Th17 pathways [inter-
associated with a decrease in circulating γδ T cells. Further,
leukin (IL)-6, IL-17, and IL-23] and elevation of Treg
particularly of some subtypes, γδ T cells, which have been
in patients with osteoporosis treated with bisphosphonates
associated with the acute-phase response (APR)20,21,22. The
factor-α. We observed that the proportion of circulating γδ
T cells is an important determinant of the occurrence of APR
after administration of N-BP, and that N-BP treatment is
still be receiving treatment, it should be stated that 60% of
patients followed over 2 years were receiving active
treatment with GC.

Therefore, most patients with PMR are at risk of becoming
chronic GC users, and they will encounter serious adverse
events that can occur in the long term even with a low dose
(i.e., < 7.5 mg daily) of prednisone. In line with previous
experiences15,16,17, these patients had clinical features of a
more severe disease course (higher inflammatory markers,
lower hemoglobin, peripheral joint involvement, and frequent
relapses), suggesting that this subgroup of patients with PMR
may benefit the most from alternative treatments to GC.

Novel approaches to spare GC in PMR have been investi-
gated, albeit with unconvincing or very preliminary
results3,18. Considering this, an innovative approach of our
study is investigating whether the use of N-BP can affect the
clinical outcome of PMR. N-BP is prescribed in 13–80%10,19
of GC-treated cases. Only 62.3% of our study patients had
been prescribed N-BP, despite GIOP being a well-known risk
factor for frailty fractures and that the Italian National Health
System reimburses it as a prophylactic treatment. Neverthe-
less, we found that our patients with PMR treated with N-BP
had on average a 35% lower risk of persisting on active
treatment with GC during their followup.

Several studies have investigated the relationships among
inflammatory diseases, pathways targeted by N-BP, and the
immune system. The use of N-BP has been associated with
longterm alterations in peripheral white blood cells and
particularly of some subtypes, γδ T cells, which have been
associated with the acute-phase response (APR)20,21,22. The
use of N-BP is occasionally associated with APR and it is
linked to the activation of γδ T cells and the release of the
pyrogenic cytokines such as interferon-γ and tumor necrosis
factor-α. We observed that the proportion of circulating γδ
T cells is an important determinant of the occurrence of APR
after administration of N-BP, and that N-BP treatment is
associated with a decrease in circulating γδ T cells. Further,
in patients with osteoporosis treated with bisphosphonates
for 1 year, a significant reduction of Th17 pathways [inter-
leukin (IL)-6, IL-17, and IL-23] and elevation of Treg
cytokine cascade (IL-10, transforming growth factor-β) can
occur23. Interestingly, it has been shown that in PMR there
may be an imbalance in the Th17:Treg ratio skewed toward
Th17, possibly contributing to its pathogenesis24.

Of note, the use of N-BP was associated with a shorter
duration of treatment independent of the initial dose of
prednisone, which was only marginally associated with the
outcome. Not surprisingly, the use of N-BP was associated
with osteoporosis, which was in turn associated with the
hazard of GC discontinuation, because a treatment with N-BP
is more likely in these patients. Female sex was not
associated with longterm GC use, in contrast with previous
studies25,26, but consistent with the more frequent use of
N-BP in women. Accordingly, the missed correlation between
female sex and active GC treatment that has been observed
in previous research27,28 might be explained by the greater
proportion of women who could have benefitted from N-BP
agents.

We acknowledge that our study, though original, has
several limitations. First, the retrospective design does not
allow for the assumption of a causal relationship between the
use of N-BP and the outcome. Second, the method we used
for extracting data from our cohort has not been validated.
Finally, some population characteristics such as the initial
prednisone dose could have led to biased results, and other
individual factors (e.g., concomitant osteoporosis) could have
driven the clinician’s decision to discontinue GC treatment.
Nonetheless, our observational study has some strengths,
including the number of patients (one of the highest among
observational studies in PMR), and investigation of N-BP as
potential disease modifiers in PMR, which has never been
analyzed before, to our knowledge.

Longterm treatment with GC in PMR is often necessary
despite current guidelines recommending GC discontinuation
after a relatively short-term course. However, this finding has
no immediate justification and the results of our study
encourage investigation of other treatments than GC for the
management of PMR. Considering this, N-BP may have be
involved in the management of PMR, and further research on
this topic is warranted. It would be of interest to analyze both
the incidence of PMR in patients exposed to N-BP and the
clinical effects of their use in patients with PMR.

REFERENCES
1. Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia
rheumatica and giant cell arteritis: a systematic review. JAMA
2016;315:2442-58.
2. González-Gay MA, Matteson EL, Castaneda S. Polymyalgia
3. Dejaco C, Brouwer E, Mason JC, Buttgereit F, Matteson EL,
Dasgupta B. Giant cell arteritis and polymyalgia rheumatica: current
Duration of therapy and long-term outcome. Am J Med
5. Fardet L, Petersen I, Nazareth I. Prevalence of long-term oral

Giollo, et al: Bisphosphonates for PMR
glucocorticoid prescriptions in the UK over the past 20 years. Rheumatology 2011;50:1982-90.


